Trial site
Frankfurt am Main
Frankfurt am Main, Hesse 60590, GermanyNot linked to an institution yet
- 6running trials
- 16closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 25 trials
- Phase 42 trials
- Phase 11 trial
- Status
- Completed14 trials
- Active, not recruiting3 trials
- Recruiting3 trials
- Terminated2 trials
- Lead sponsor
- Novartis Pharmaceuticals22 trials
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
NCT06097663· Phase 2· Novartis Pharmaceuticals· Source
Completed
Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care
NCT06004453· Novartis Pharmaceuticals· Source
Completed
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
NCT05562934· Phase 2· Novartis Pharmaceuticals· Source
Completed
Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies
NCT05566756· Novartis Pharmaceuticals· Source
Recruiting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
NCT05344469· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Completed
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
NCT05192941· Phase 4· Novartis Pharmaceuticals· Source
Terminated
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NCT04952753· Phase 2· Novartis Pharmaceuticals· Source
Completed
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
NCT04948333· Phase 3· Novartis Pharmaceuticals· Source
Completed
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
NCT04679935· Phase 4· Novartis Pharmaceuticals· Source
Completed
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
NCT04543331· Novartis Pharmaceuticals· Source
Terminated
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301· Phase 3· Novartis Pharmaceuticals· Source
Completed
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· Phase 3· Novartis Pharmaceuticals· Source
Completed
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
NCT03798626· Phase 1· Novartis Pharmaceuticals· Source
Completed
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
NCT03106779· Phase 3· Novartis Pharmaceuticals· Source
Completed
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
NCT06311383· Novartis Pharmaceuticals· Source
Completed
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784068· Phase 2· Novartis Pharmaceuticals· Source
Report an error